Relay Therapeutics, Inc.
RLAY
Peringkat dalam Saham
#4010
Relay Therapeutics, Inc. is a precision medicine company currently engaged in... Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
Harga Saham
$18.65
Terakhir disinkronkan: 2026-10-20
Kapitalisasi Pasar
$4.09B
Perubahan (1 hari)
9.15%
Perubahan (1 tahun)
164.96%
Negara
US
Perdagangan Relay Therapeutics, Inc. (RLAY)
Kategori
Healthcare
Rasio P/E untuk Relay Therapeutics, Inc. (RLAY)
Rasio P/E per October 2026 TTM: -10.87
Menurut laporan keuangan dan harga saham terbaru dari Relay Therapeutics, Inc., rasio P/E saat ini (TTM) adalah -10.87. Pada akhir 2023, perusahaan memiliki rasio P/E sebesar -3.95.
Riwayat rasio P/E untuk Relay Therapeutics, Inc. dari 2018 hingga 2026
Rasio P/E di akhir setiap tahun
| Tahun | Rasio P/E | Mengubah |
|---|---|---|
| 2026 (TTM) | -10.87 | 524.49% |
| 2024 | -1.74 | -55.83% |
| 2023 | -3.95 | -31.63% |
| 2022 | -5.77 | -28.12% |
| 2021 | -8.03 | -88.76% |
| 2020 | -71.41 | 3,064.77% |
| 2019 | -2.26 | 26.37% |
| 2018 | -1.79 | 0.00% |
Rasio P/E untuk perusahaan serupa atau pesaing
| Perusahaan | Rasio P/E | Perbedaan Rasio P/E | Negara |
|---|---|---|---|
| 28.78 | -364.87% |
US
|
|
| -28.36 | 160.98% |
US
|
|
| -24.57 | 126.09% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -379.12% |
NL
|
Bagaimana cara membaca P/E ratio?
Rasio Harga/Laba (P/E) mengukur hubungan antara harga saham perusahaan dan laba per sahamnya.
P/E yang rendah namun positif menunjukkan perusahaan dengan laba tinggi dibandingkan valuasinya saat ini dan mungkin dianggap undervalued. P/E negatif tinggi (mendekati 0) menunjukkan perusahaan yang mengalami kerugian besar.
Perusahaan dengan P/E di atas 30 atau negatif umumnya dianggap sebagai "saham pertumbuhan", artinya investor mengharapkan pertumbuhan atau keuntungan di masa depan.
Perusahaan dengan P/E positif di bawah 10 dianggap sebagai "saham bernilai", artinya perusahaan sudah sangat menguntungkan dan pertumbuhannya kemungkinan tidak besar.